** Shares of LTR Pharma rise 7.9% to A$0.755
** The biopharmaceutical firm rose as much as 17.9% earlier in the day, their biggest intraday gain since early November
** Co enters an agreement with Australian pharmaceutical wholesaler Symbion for nation-wide distribution for SPONTAN
** SPONTAN is LTR Pharma's lead product for treatment of erectile dysfunction
** About 1.2 mln shares change hands, compared with 30-day average trading volume of 669,941 shares
** Stock down 13.6% YTD, as of last close
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))